|
[1]
|
Lamerz, R. (1999) Role of Tumour Markers, Cytogenetics. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 10, 145-149. [Google Scholar] [CrossRef]
|
|
[2]
|
Huang, Z. and Liu, F. (2014) Diagnostic Value of Serum Carbohydrate Antigen 19-9 in Pancreatic Cancer: A Meta-Analysis. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 35, 7459-7465. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Levy, C., Lymp, J., Angulo, P., et al. (2005) The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 50, 1734-1740. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Marrelli, D., Caruso, S., Pedrazzani, C., et al. (2009) CA19-9 Serum Levels in Obstructive Jaundice: Clinical Value in Benign and Malignant Conditions. American Journal of Surgery, 198, 333-339. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Hata, S., Sakamoto, Y., Yamamoto, Y., et al. (2012) Prognostic Impact of Postoperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer. Annals of Surgical Oncology, 19, 636-641. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Steinberg, W. (1990) The Clinical Utility of the CA 19-9 Tumor-Associated Antigen. The American Journal of Gastroenterology, 85, 350-355.
|
|
[7]
|
Kim, J., Lee, Y.S., Hwang, I.K., et al. (2015) Postoperative Carcinoembryonic Antigen as a Complementary Tumor Marker of Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma. Journal of Korean Medical Science, 30, 259-263. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Poruk, K.E., Gay, D.Z., Brown, K., et al. (2013) The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. Current Molecular Medicine, 13, 340-351. [Google Scholar] [CrossRef]
|
|
[9]
|
Luo, G., Liu, C., Guo, M., et al. (2017) Potential Biomarkers in Lewis Negative Patients with Pancreatic Cancer. Annals of Surgery, 265, 800-805. [Google Scholar] [CrossRef]
|
|
[10]
|
Gu, Y.L., Lan, C., Pei, H., et al. (2015) Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy. Asian Pacific Journal of Cancer Prevention: APJCP, 16, 6569-6573. [Google Scholar] [CrossRef]
|
|
[11]
|
van Manen, L., Groen, J.V., Putter, H., et al. (2020) Elevated CEA and CA19-9 Serum Levels Independently Predict Advanced Pancreatic Cancer at Diagnosis. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 25, 186-193. [Google Scholar] [CrossRef]
|
|
[12]
|
Saluja, A. and Dudeja, V. (2008) Heat Shock Proteins in Pancreatic Diseases. Journal of Gastroenterology and Hepatology, 23, S42-S45. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Schäfer, C., Seeliger, H., Bader, D.C., et al. (2012) Heat Shock Protein 27 as a Prognostic and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma. Journal of Cellular and Molecular Medicine, 16, 1776-1791. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Sun, C., Rosendahl, A.H., Ansari, D., et al. (2011) Proteome-Based Biomarkers in Pancreatic Cancer. World Journal of Gastroenterology, 17, 4845-4852. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., et al. (2007) Proteomics Finding Heat Shock Protein 27 as a Biomarker for Resistance of Pancreatic Cancer Cells to Gemcitabine. International Journal of Oncology, 31, 1345-1350. [Google Scholar] [CrossRef]
|
|
[16]
|
Duarte, B.D.P. and Bonatto, D. (2018) The Heat Shock Protein 47 as a Potential Biomarker and a Therapeutic Agent in Cancer Research. Journal of Cancer Research and Clinical Oncology, 144, 2319-2328. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Dutta, S.K., Girotra, M., Singla, M., et al. (2012) Serum HSP70: A Novel Biomarker for Early Detection of Pancreatic Cancer. Pancreas, 41, 530-534. [Google Scholar] [CrossRef]
|
|
[18]
|
Kosanam, H., Prassas, I., Chrystoja, C.C., et al. (2013) Laminin, Gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues. Molecular & Cellular Proteomics: MCP, 12, 2820-2832. [Google Scholar] [CrossRef]
|
|
[19]
|
Zhang, X., Huang, S., Guo, J., et al. (2016) Insights into the Distinct Roles of MMP-11 in Tumor Biology and Future Therapeutics (Review). International Journal of Oncology, 48, 1783-1793. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Lee, J., Lee, J. and Kim, J.H. (2019) Identification of Matrix Metalloproteinase 11 as a Prognostic Biomarker in Pancreatic Cancer. Anticancer Research, 39, 5963-5971. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Honda, K., Kobayashi, M., Okusaka, T., et al. (2015) Plasma Biomarker for Detection of Early Stage Pancreatic Cancer and Risk Factors for Pancreatic Malignancy Using Antibodies for Apolipoprotein-AII Isoforms. Scientific Reports, 5, Article No. 15921. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kuwatani, M., Kawakami, H., Kubota, Y., et al. (2019) Verification of the Effectiveness of Fucosylated Haptoglobin as a Pancreatic Cancer Marker in Clinical Diagnosis. Pancreatology: Official Journal of the International Association of Pancreatology (IAP), 19, 569-577. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Jenkinson, C., Elliott, V., Menon, U., et al. (2015) Evaluation in Pre-Diagnosis Samples Discounts ICAM-1 and TIMP-1 as Biomarkers for Earlier Diagnosis of Pancreatic Cancer. Journal of Proteomics, 113, 400-402. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Kishikawa, T., Otsuka, M., Ohno, M., et al. (2015) Circulating RNAs as New Biomarkers for Detecting Pancreatic Cancer. World Journal of Gastroenterology, 21, 8527-8540. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Bartel, D.P. (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136, 215-233. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Brennecke, J., Stark, A., Russell, R.B., et al. (2005) Principles of microRNA-Target Recognition. PLoS Biology, 3, e85. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Munker, R. and Calin, G.A. (2011) MicroRNA Profiling in Cancer. Clinical Science (London, England: 1979), 121, 141-158. [Google Scholar] [CrossRef]
|
|
[28]
|
Qu, K., Zhang, X., Lin, T., et al. (2017) Circulating miRNA-21-5p as a Diagnostic Biomarker for Pancreatic Cancer: Evidence from Comprehensive miRNA Expression Profiling Analysis and Clinical Validation. Scientific Reports, 7, Article No. 1692. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Li, A., Yu, J., Kim, H., et al. (2013) MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19, 3600-3610. [Google Scholar] [CrossRef]
|
|
[30]
|
Fleischhacker, M. and Schmidt, B. (2007) Circulating Nucleic Acids (CNAs) and Cancer—A Survey. Biochimica et Biophysica Acta, 1775, 181-232. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Yi, J.M., Guzzetta, A.A., Bailey, V.J., et al. (2013) Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19, 6544-6555. [Google Scholar] [CrossRef]
|
|
[32]
|
Eissa, M.A.L., Lerner, L., Abdelfatah, E., et al. (2019) Promoter Methylation of ADAMTS1 and BNC1 as Potential Biomarkers for Early Detection of Pancreatic Cancer in Blood. Clinical Epigenetics, 11, 59. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Li, S., Wang, L., Zhao, Q., et al. (2020) Genome-Wide Analysis of Cell-Free DNA Methylation Profiling for the Early Diagnosis of Pancreatic Cancer. Frontiers in Genetics, 11, Article ID: 596078. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Zhou, H., Zhu, Y., Wei, F., et al. (2019) Significance of MUC2 Gene Methylation Detection in Pancreatic Cancer Diagnosis. Pancreatology: Official Journal of the International Association of Pancreatology (IAP), 19, 1049-1053. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Li, X.B., Ma, J., Liu, Z.W., et al. (2019) Non-Invasive Detection of Pancreatic Cancer by Measuring DNA Methylation of Basonuclin 1 and Septin 9 in Plasma. Chinese Medical Journal, 132, 1504-1506. [Google Scholar] [CrossRef]
|
|
[36]
|
Chang, J.C. and Kundranda, M. (2017) Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. International Journal of Molecular Sciences, 18, 667. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Tao, L., Zhou, J., Yuan, C., et al. (2019) Metabolomics Identifies Serum and Exosomes Metabolite Markers of Pancreatic Cancer. Metabolomics: Official Journal of the Metabolomic Society, 15, 86. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Herreros-Villanueva, M. and Bujanda, L. (2016) Glypican-1 in Exosomes as Biomarker for Early Detection of Pancreatic Cancer. Annals of Translational Medicine, 4, 64. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Melo, S.A., Luecke, L.B., Kahlert, C., et al. (2015) Glypican-1 Identifies Cancer Exosomes and Detects Early Pancreatic Cancer. Nature, 523, 177-182. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Xiao, D., Dong, Z., Zhen, L., et al. (2020) Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer. Molecular Cancer Research: MCR, 18, 300-310. [Google Scholar] [CrossRef]
|
|
[41]
|
Buscail, E., Chauvet, A., Quincy, P., et al. (2019) CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Translational Oncology, 12, 1395-1403. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Kimura, H., Yamamoto, H., Harada, T., et al. (2019) CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 1936-1947. [Google Scholar] [CrossRef]
|
|
[43]
|
Lux, A., Kahlert, C., Grützmann, R., et al. (2019) c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. International Journal of Molecular Sciences, 20, 3305. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Que, R., Ding, G., Chen, J., et al. (2013) Analysis of Serum Exosomal microRNAs and Clinicopathologic Features of Patients with Pancreatic Adenocarcinoma. World Journal of Surgical Oncology, 11, 219. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Poruk, K.E., Valero, V., Saunders, T., et al. (2016) Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 264, 1073-1081. [Google Scholar] [CrossRef]
|
|
[46]
|
Allard, W.J., Matera, J., Miller, M.C., et al. (2004) Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas But Not in Healthy Subjects or Patients with Nonmalignant Diseases. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 6897-6904. [Google Scholar] [CrossRef]
|
|
[47]
|
Court, C.M., Ankeny, J.S., Sho, S., et al. (2016) Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. The Journal of Molecular Diagnostics: JMD, 18, 688-696. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Rhim, A., Mirek, E., Aiello, N., et al. (2012) EMT and Dissemination Precede Pancreatic Tumor Formation. Cell, 148, 349-361. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Feng, L., Qi, Q., Wang, P., et al. (2018) Serum Levels of IL-6, IL-8, and IL-10 Are Indicators of Prognosis in Pancreatic Cancer. The Journal of International Medical Research, 46, 5228-5236. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Shaw, V.E., Lane, B., Jenkinson, C., et al. (2014) Serum Cytokine Biomarker Panels for Discriminating Pancreatic Cancer from Benign Pancreatic Disease. Molecular Cancer, 13, 114. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Babic, A., Schnure, N., Neupane, N.P., et al. (2018) Plasma Inflammatory Cytokines and Survival of Pancreatic Cancer Patients. Clinical and Translational Gastroenterology, 9, 145. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Litman-Zawadzka, A., Łukaszewicz-Zając, M., Gryko, M., et al. (2018) Serum Chemokine CXCL8 as a Better Biomarker for Diagnosis and Prediction of Pancreatic Cancer than Its Specific Receptor CXCR2, C-Reactive Protein, and Classic Tumor Markers CA 19-9 and CEA. Polish Archives of Internal Medicine, 128, 524-531. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Fogelman, D.R., Morris, J., Xiao, L., et al. (2017) A Predictive Model of Inflammatory Markers and Patient-Reported Symptoms for Cachexia in Newly Diagnosed Pancreatic Cancer Patients. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 25, 1809-1817. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Furukawa, K., Kawamoto, K., Eguchi, H., et al. (2015) Clinicopathological Significance of Leucine-Rich α2-Glyco- protein-1 in Sera of Patients with Pancreatic Cancer. Pancreas, 44, 93-98. [Google Scholar] [CrossRef]
|